Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2019-10-01
DOI
10.1080/10428194.2019.1663423
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of performance status and transfusion dependency on outcome of patients with MDS, AML and CMML treated with Azacitidine (PIAZA study)
- (2018) J Wehmeyer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
- (2017) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database
- (2016) Sean A. Fletcher et al. CANCER
- Emerging biological therapies for the treatment of myelodysplastic syndromes
- (2016) Amer M. Zeidan et al. EXPERT OPINION ON EMERGING DRUGS
- Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2016) Peter L. Greenberg et al. Journal of the National Comprehensive Cancer Network
- Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
- (2015) T Bernal et al. LEUKEMIA
- Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
- (2015) A M Zeidan et al. LEUKEMIA
- Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
- (2014) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes
- (2014) David P. Steensma et al. CANCER
- Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA®registry
- (2014) David L. Grinblatt et al. LEUKEMIA & LYMPHOMA
- Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
- (2014) Valeria Santini et al. LEUKEMIA RESEARCH
- Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies
- (2014) Amy J. Davidoff et al. MEDICAL CARE
- Concise Drug Review: Azacitidine and Decitabine
- (2013) E. J. B. Derissen et al. ONCOLOGIST
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Thrombocytopenia in Patients With Myelodysplastic Syndromes
- (2010) Jeffrey Bryan et al. SEMINARS IN HEMATOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started